BR112018074483A2 - proteínas f do rsv pré-fusão estabilizadas - Google Patents

proteínas f do rsv pré-fusão estabilizadas

Info

Publication number
BR112018074483A2
BR112018074483A2 BR112018074483-2A BR112018074483A BR112018074483A2 BR 112018074483 A2 BR112018074483 A2 BR 112018074483A2 BR 112018074483 A BR112018074483 A BR 112018074483A BR 112018074483 A2 BR112018074483 A2 BR 112018074483A2
Authority
BR
Brazil
Prior art keywords
proteins
fusion rsv
stabilized pre
rsv
stabilized
Prior art date
Application number
BR112018074483-2A
Other languages
English (en)
Inventor
Petrus Maria Langedijk Johannes
Original Assignee
Janssen Vaccines & Prevention B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention B.V. filed Critical Janssen Vaccines & Prevention B.V.
Publication of BR112018074483A2 publication Critical patent/BR112018074483A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção proporciona proteínas f do vírus sincicial respiratório (rsv) pré-fusão estáveis, composições imunogênicas compreendendo as referidas proteínas e usos das mesmas para a prevenção e/ou tratamento de infecção pelo rsv.
BR112018074483-2A 2016-05-30 2017-05-29 proteínas f do rsv pré-fusão estabilizadas BR112018074483A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16172008.1 2016-05-30
EP16172008 2016-05-30
PCT/EP2017/062875 WO2017207480A1 (en) 2016-05-30 2017-05-29 Stabilized pre-fusion rsv f proteins

Publications (1)

Publication Number Publication Date
BR112018074483A2 true BR112018074483A2 (pt) 2019-03-19

Family

ID=56131313

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074483-2A BR112018074483A2 (pt) 2016-05-30 2017-05-29 proteínas f do rsv pré-fusão estabilizadas

Country Status (21)

Country Link
US (2) US10953087B2 (pt)
EP (1) EP3464331B1 (pt)
JP (1) JP2019523644A (pt)
KR (1) KR102421049B1 (pt)
CN (1) CN109311946A (pt)
AU (2) AU2017272504A1 (pt)
BR (1) BR112018074483A2 (pt)
CA (1) CA3025441A1 (pt)
CL (1) CL2018003383A1 (pt)
DK (1) DK3464331T3 (pt)
EA (1) EA039124B1 (pt)
ES (1) ES2836598T3 (pt)
IL (1) IL264119B2 (pt)
MX (1) MX2018014699A (pt)
MY (1) MY194419A (pt)
PE (1) PE20190110A1 (pt)
PH (1) PH12018502332A1 (pt)
PL (1) PL3464331T3 (pt)
SG (1) SG11201810078PA (pt)
WO (1) WO2017207480A1 (pt)
ZA (1) ZA201808094B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
US10456462B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Preventions B.V. Vaccine against RSV
PE20190433A1 (es) 2016-04-05 2019-03-21 Janssen Vaccines And Prevention B V Vacuna contra vrs
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
MX2019011869A (es) 2017-04-04 2020-01-09 Univ Washington Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
US11771755B2 (en) 2018-02-28 2023-10-03 University Of Washington Self-asssembling nanostructure vaccines
US20220017574A1 (en) * 2018-11-13 2022-01-20 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
WO2021046207A1 (en) 2019-09-04 2021-03-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN115461076A (zh) 2020-04-02 2022-12-09 扬森疫苗与预防公司 稳定化的疫苗组合物

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5994108A (en) 1991-11-05 1999-11-30 Board Of Regents, The University Of Texas System Mutant TAR virus and transdominant tat mutants as pharmacological agents
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
KR20050043996A (ko) 1996-07-01 2005-05-11 아방티 파르마 소시에테 아노님 재조합 아데노바이러스의 제조방법
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
CA2272820C (en) 1996-11-20 2012-09-11 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US5851808A (en) 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
EP0973866A4 (en) 1997-03-04 2000-04-19 Baxter Int ADENOVIRUS E1-COMPLEMENTING CELL LINES
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
AU757976B2 (en) 1998-02-17 2003-03-13 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
EP1133316B1 (en) 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
PT1550722E (pt) 1999-05-17 2007-09-25 Crucell Holland Bv ''adenovírus humano recombinante do serótipo 35''
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6281823B1 (en) 1999-09-21 2001-08-28 Agere Systems Guardian Corp. Direct digital synthesis using a sine weighted DAC
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
AU4346101A (en) 2000-03-07 2001-09-17 Merck & Co., Inc. Adenovirus formulations
NZ523036A (en) 2000-05-08 2004-04-30 Davisco Foods Internat Inc Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals
US6861529B2 (en) 2001-07-06 2005-03-01 Pfizer Inc Cycloalkypyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
MXPA04006995A (es) 2002-01-18 2005-07-13 Schering Ag Formulaciones estabilizadas de adenovirus.
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
MXPA04008891A (es) 2002-04-25 2004-11-26 Crucell Holland Bv Medios y metodos para la produccion de vectores de adenovirus.
KR101006594B1 (ko) 2002-04-25 2011-01-07 크루셀 홀란드 비.브이. 안정한 아데노바이러스 벡터 및 그 증식 방법
ATE494362T1 (de) 2002-05-14 2011-01-15 Merck Sharp & Dohme Verfahren zur reinigung von adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
AU2003268210A1 (en) 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
DK1711518T3 (da) 2004-01-23 2010-04-06 Angeletti P Ist Richerche Bio Vaccinebærere for chimpanse-adenovirus
CN101343625A (zh) 2004-02-23 2009-01-14 克鲁塞尔荷兰公司 病毒纯化方法
DE602006003420D1 (de) 2005-04-11 2008-12-11 Crucell Holland Bv Virusreinigung mit ultrafiltration
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
US8772256B2 (en) 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
KR101617895B1 (ko) 2007-12-24 2016-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 재조합 ｒｓｖ 항원
ATE545028T1 (de) 2008-02-29 2012-02-15 Tibotec Pharm Ltd Verfahren zur identifizierung von inhibitoren gegen viren, die ein klasse-i-fusionsprotein verwenden
US8225289B2 (en) 2008-03-04 2012-07-17 Wind River Systems, Inc. Method and system for improved tool interaction with a target
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
RU2531510C2 (ru) 2008-12-09 2014-10-20 Новавакс, Инк. Модифицированные f протеины sv и способы их применения
CN101464897A (zh) 2009-01-12 2009-06-24 阿里巴巴集团控股有限公司 一种词匹配及信息查询方法及装置
AU2010209938A1 (en) 2009-02-02 2011-08-25 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
KR101696002B1 (ko) 2009-06-24 2017-01-13 글락소스미스클라인 바이오로지칼즈 에스.에이. 재조합 ｒｓｖ 항원
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
RU2585227C2 (ru) 2009-07-15 2016-05-27 Новартис Аг Композиции белка f rsv и способы их получения
KR101778317B1 (ko) 2009-08-13 2017-09-13 얀센 백신스 앤드 프리벤션 비.브이. 사람 호흡기 세포융합 바이러스(ｒｓｖ)에 대한 항체 및 이용 방법
BR112012008507B8 (pt) 2009-10-15 2021-05-25 Crucell Holland Bv método para purificar partículas de adenovírus a partir de uma suspensão de célula
AU2010305765B2 (en) 2009-10-15 2015-07-02 Crucell Holland B.V. Method for the purification of adenovirus particles
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
WO2011098592A1 (en) 2010-02-15 2011-08-18 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
US8772258B2 (en) 2010-07-02 2014-07-08 Ensysce Biosciences, Inc. Single walled carbon nanotube/sirna complexes and methods related thereto
AR082149A1 (es) 2010-07-09 2012-11-14 Calmune Corp Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
US8317672B2 (en) 2010-11-19 2012-11-27 Kensey Nash Corporation Centrifuge method and apparatus
JP2014519819A (ja) 2011-05-13 2014-08-21 ノバルティス アーゲー 融合前ｒｓｖｆ抗原
HUE027839T2 (en) 2012-03-12 2016-11-28 Crucell Holland Bv Recombinant adenoviruses with altered terminals
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SG11201405804YA (en) 2012-03-22 2014-10-30 Crucell Holland Bv Vaccine against rsv
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
JP6210998B2 (ja) 2012-11-15 2017-10-11 一般財団法人化学及血清療法研究所 ベクターワクチンおよび生ワクチンの併用による感染症の予防方法
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
JP6703475B2 (ja) 2013-03-13 2020-06-03 アメリカ合衆国 融合前ｒｓｖｆタンパク質およびそれらの使用
JP6506249B2 (ja) * 2013-03-14 2019-04-24 エモリー ユニバーシティー サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
WO2014153160A2 (en) 2013-03-14 2014-09-25 Peroxyium, Inc., Delaware C Corp. METHOD OF ENHANCING THE BIODISTRIBUTION AND TISSUE TARGETING PROPERTIES OF THERAPEUTIC CeO2 PARTICLES VIA NANO-ENCAPSULATION AND COATING
US9060975B2 (en) * 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
EA035846B1 (ru) 2013-04-15 2020-08-20 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv
KR102201554B1 (ko) 2013-04-15 2021-01-12 얀센 백신스 앤드 프리벤션 비.브이. Ｒｓｖ ｇ 단백질에 결합하는 인간 항체
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
SG11201510216RA (en) 2013-06-17 2016-01-28 Crucell Holland Bv Stabilized soluble pre-fusion rsv f polypeptides
JP6685903B2 (ja) * 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー 立体構造的に安定化されたｒｓｖ融合前ｆタンパク質
PE20160527A1 (es) 2013-09-19 2016-05-20 Crucell Holland Bv Formulaciones de adenovirus mejoradas
EP3888676A1 (en) 2014-06-13 2021-10-06 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
JP6350376B2 (ja) 2015-04-23 2018-07-04 住友金属鉱山株式会社 非水系電解質二次電池用正極活物質及びその製造方法、並びにその正極活物質を用いた非水系電解質二次電池
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
US10456462B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Preventions B.V. Vaccine against RSV
PE20190433A1 (es) 2016-04-05 2019-03-21 Janssen Vaccines And Prevention B V Vacuna contra vrs
CN109069616A (zh) 2016-04-05 2018-12-21 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f蛋白
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US10522129B2 (en) 2016-10-06 2019-12-31 Gopro, Inc. Active acoustic and vibration noise canceling in waterproof camera
KR20180056310A (ko) 2016-11-18 2018-05-28 삼성전자주식회사 복합양극활물질, 이를 채용한 양극과 리튬전지 및 그 제조방법
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EA202090738A1 (ru) 2017-09-15 2020-06-10 Янссен Вэксинс Энд Превеншн Б.В. Способ безопасного индуцирования иммунитета против rsv
US20220017574A1 (en) 2018-11-13 2022-01-20 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CN113597428A (zh) 2019-04-25 2021-11-02 扬森疫苗与预防公司 重组流感抗原
CA3140234A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
CN115461076A (zh) 2020-04-02 2022-12-09 扬森疫苗与预防公司 稳定化的疫苗组合物
AU2021302535A1 (en) 2020-06-29 2023-02-09 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection

Also Published As

Publication number Publication date
CA3025441A1 (en) 2017-12-07
EP3464331A1 (en) 2019-04-10
US10953087B2 (en) 2021-03-23
MY194419A (en) 2022-11-30
SG11201810078PA (en) 2018-12-28
AU2021232702A1 (en) 2021-10-14
EA039124B1 (ru) 2021-12-08
IL264119B (en) 2022-12-01
PE20190110A1 (es) 2019-01-15
EP3464331B1 (en) 2020-10-28
AU2017272504A1 (en) 2018-11-29
EA201892702A1 (ru) 2019-05-31
US20210205440A1 (en) 2021-07-08
DK3464331T3 (da) 2021-01-18
CN109311946A (zh) 2019-02-05
WO2017207480A1 (en) 2017-12-07
IL264119B2 (en) 2023-04-01
US20200138940A1 (en) 2020-05-07
PH12018502332A1 (en) 2019-05-15
ZA201808094B (en) 2022-05-25
KR20190012193A (ko) 2019-02-08
AU2021232702B2 (en) 2023-11-02
CL2018003383A1 (es) 2019-01-18
KR102421049B1 (ko) 2022-07-15
JP2019523644A (ja) 2019-08-29
MX2018014699A (es) 2019-02-28
IL264119A (en) 2019-02-28
ES2836598T3 (es) 2021-06-25
PL3464331T3 (pl) 2021-04-19
US11759514B2 (en) 2023-09-19

Similar Documents

Publication Publication Date Title
BR112018074483A2 (pt) proteínas f do rsv pré-fusão estabilizadas
BR112017028449A2 (pt) polipeptídeos rsv f pré-fusão solúveis estabilizados
CY1121600T1 (el) Σταθεροποιημενα διαλυτα πολυπεπτιδια rsv f προσυντηξης
BR112018070013A2 (pt) proteínas f do rsv pré-fusão solúveis estabilizadas
BR112015031509A2 (pt) Polipeptídeo, molécula de ácido nucleico, vetor, e, composição
CO2021006308A2 (es) Proteínas f de prefusión del vrs estabilizadas
BR112017018022A2 (pt) "compostos antivirais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
EA201070794A1 (ru) Рекомбинантные антигены rsv
BR112018011085A2 (pt) composições farmacêuticas contendo doravirina, fumarato de tenofovir desoproxila e lamivudina
BR112017016110A2 (pt) composições de imunoglobulina equina e usos para tratamento de doenças mediadas por filovírus
CL2017003260A1 (es) Dominios variables simples de inmunoglobulina contra proteína f de rsv.
EA201890209A1 (ru) Композиция, содержащая танины
EA201992167A1 (ru) Вакцина

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]